When she saw vaping taking hold at a middle school, Kamala Nola, PharmD, MS, spoke up about concerns for the students’ risk of rheumatic disease and other health issues. At ACR Convergence 2022, Dr. Nola emphasized that every healthcare professional can act as an advocate through everyday actions.
Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease
Data from a small study show that severe methotrexate toxicity in patients who are 70 years of age and older and have rheumatic disease may be associated with poor renal function and the use of diuretic treatments.
Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw
A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.
Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.
Tuhina Neogi, MD, PhD, Returns to Lead the Committee on Quality of Care
Dr. Neogi has returned to the ACR Committee on Quality of Care as its new chair after years of dedicated work developing classification criteria, outcome measures and treatment guidelines for rheumatoid arthritis, gout and other rheumatic diseases.
Are You Listening? Young Patient Advocates Call for Change
PHILADELPHIA—Representatives of the Young Patients’ Autoimmune Research and Empowerment Alliance (YP AREA) led a panel titled Young Patients with Big Ideas Will Revolutionize Healthcare and Research, in which they discussed their work as advocates for adolescent and young adult (AYA) patients. YP AREA’s mission is to make autoimmune research more accessible and inclusive by involving…
COVID-19 Vaccine Responses Among the Immunosuppressed
PHILADELPHIA—Patients with rheumatic diseases often mount an adequate immune response after receiving COVID-19 vaccinations, but that is not always the case, and certain medications make patients more prone to having an insufficient response, said Judith James, MD, PhD, chair, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, at an ACR Convergence…
Contraception, Abortion & Rheumatic Disease after Dobbs
PHILADELPHIA—As rheumatologists, we care for patients who may or may not want to become pregnant. We aren’t obstetricians or gynecologists, but several of the drugs we prescribe for active rheumatic disease can negatively affect pregnancy outcomes. It’s imperative we understand how to effectively counsel our patients with rheumatic disease on the risks and benefits of…
An Integrative Approach to the Treatment of Rheumatoid Arthritis
PHILADELPHIA—It is often the case that a holistic approach to the management of autoimmune disease is what patients are looking for and may indeed provide optimal care for these patients. At ACR Convergence 2022, the session titled ACR Guideline for Physical, Psychosocial, Mind-Body and Nutritional Interventions for Rheumatoid Arthritis: An Integrative Approach to Treatment sought…
Pseudo-What? Exploring the Classification Criteria Development Process for CPPD
PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 815
- Next Page »